Press releases

Advanced Search
  • Aug 7, 2014
    Fourth quarter revenue of $1.12 billion, up 24 percent; Fiscal 2014 revenue of $3.84 billion, up 8 percent.

    SAN DIEGO, Aug. 7, 2014/PRNewswire/ – CareFusion Corp. (NYSE: CFN), a leading, global medical technology company, today reported results for the quarter and fiscal year ended June 30, 2014,...

  • Aug 6, 2014
    The only pen needle with patented dual needle shields for enhanced convenience and safety is latest BD innovation for insulin injection

    FRANKLIN LAKES, N.J., August 6, 2014 – BD Medical, a segment of BD (Becton, Dickinson and Company) (NYSE: BDX), a leading global medical technology company, today announced the retail pharmacy...

  • Aug 4, 2014
    Total Nucleic Acid Reagents Now Available Worldwide - Streamlined Workflow for In-House Developed Assays

    BD Diagnostics, a segment of leading global medical technology company BD (Becton, Dickinson, and Company) (NYSE: BDX), announced today the availability of the Total Nucleic Acid (TNA) suite of...

  • Jul 31, 2014
    ChloraPrep 1 mL Applicator Provides Additional Option to Proven Portfolio of Patient Skin Preparation Products

    SAN DIEGO, July 31, 2014 /PRNewswire/ – CareFusion (NYSE:CFN), a leading global medical technology company, today announced the launch of its ChloraPrep® 1 mL applicator, the newest addition to...

  • Jul 31, 2014
    - Announces revenues of $2.157 billion, an increase of 5.1 percent, or 4.6 percent on a foreign currency-neutral basis.

    BD (Becton, Dickinson and Company) (NYSE: BDX), a leading global medical technology company, today reported quarterly revenues of $2.157 billion for the third fiscal quarter ended June 30, 2014,...